First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI AND HONG KONG, Dec. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced dosing in Australia of the first subject in the Phase I PROBE Trial, a first-in-human study of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma (B-NHL). The primary objective of the study is to evaluate the safety and tolerability of ATG-101 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ATG-101; the secondary objective is to evaluate preliminary anti-tumor activity of ATG-101.

ATG-101 is a novel bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. ATG-101 demonstrated significant anti-tumor activity in animal models of resistant tumors as well as those that progressed on anti-PD-1/L1 treatment. Furthermore, no liver toxicity was observed in GLP toxicology studies in cynomolgus monkeys with doses up to 100 mg/kg.

"ATG-101 has been specifically designed to combine the proven activity of PD-1 inhibition with the immune stimulating activity of 4-1BB. Our intent is to further enhance the role of immune-oncological drugs, by turning "cold" tumors "hot" and thereby improve outcomes for patients who do not respond to anti-PD-1/PD-L1 monotherapies, or regain control of disease that has become resistant or refractory to these drugs. This has become a growing and increasingly important medical need." said Dr. Kevin Lynch, Chief Medical Officer of Antengene. "PROBE is Antengene's first global trial of an in-house developed, novel drug. The program is now enrolling patients in Australia, thereafter expanding to the U.S. where the IND has been cleared by the FDA. Dosing of the first subject is an important milestone, highlighting our cross-regional Discovery and Clinical execution capabilities. We are very grateful to the patients, investigators and study site staff for their dedication and support for this program and hope we will be able to make an important difference in cancer with ATG-101."

"As many patients with malignancies are resistant or refractory to current therapies, including chemotherapy, targeted therapy and monoclonal antibodies, there remains a need for novel treatments for this patient population," said Dr. Charlotte Lemech, Medical Director of Scientia Clinical Research in Sydney, Australia.

Dr. Lemech continued, "Accumulating evidence suggests that bispecific antibodies will fill an important role as one of these novel strategies. We are excited to be leading this clinical trial, the first to administer ATG-101 – a novel PD-L1/4-1BB bispecific antibody - bringing together a group of highly experienced Australian investigators to collaborate with Antengene. The design of ATG-101 incorporates a high affinity for PD-L1 and conditional activation of 4-1BB, which potentially reduces the risk of 4-1BB related liver toxicity. We are looking forward to assessing whether this bispecific antibody can provide enhanced efficacy with a better safety profile and a new option for these patients."

About the PROBE Trial
The PROBE trial is a first-in-human Phase I trial of ATG-101 in patients with metastatic/advanced solid tumors and mature B-cell non-Hodgkin lymphomas (B-NHL). The study will be conducted in the Dose Escalation Phase and Dose Expansion Phase, with the primary objective to evaluate the safety and tolerability of ATG-101 and to determine the MTD) and/or RP2D) of ATG-101, and the secondary objective to evaluate preliminary anti-tumor activity of ATG-101. The study will also evaluate a range of pharmacology, immunology and biomarker measurements.

About ATG-101
ATG-101 is a novel PD-L1/4-1BB bi-specific antibody being developed for the treatment of multiple kinds of cancer. ATG-101 was designed to activate anti-tumor immune effectors, by forming a cell-antibody-cell trimer to simultaneously block the binding of PD-L1/PD-1 and induce 4-1BB stimulation, with limited hepatoxicity. ATG-101 activates exhausted cells in vitro, signaling a potential in reversing T-cell dysfunction and exhaustion (on PD-1 cross-linking). In PD-L1 over-expressing cancer cells, ATG-101 demonstrated significant anti-tumor activity in animal tumors that progressed on anti-PD-1/L1 treatment and a favorable safety profile in GLP toxicology studies. Data from these studies, as well as unique computational semi-mechanistic pharmacology modeling work, was recently presented at the Society of Immunology and Cancer (SITC 2021).

About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading clinical-stage R&D- driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 20 investigational new drug (IND) approvals in the U.S. and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for selinexor/ATG-010 in South Korea and mainland China approved through a priority review process. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. The Company has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs.

Forward-Looking Statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

For more information, please contact:

Investor Contacts:
Donald Lung
E-mail: [email protected]  
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: [email protected]  
Mobile: +86 13062747000

SOURCE Antengene Corporation Limited